Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

Business Leaders

HomeAll NewsMost read newsBusiness Leaders Biography 
Portrait de Patrick van Berkel
Age : 53
Public asset : 1,683,266 USD
Country of residence : Unknown
Linked companies : ADC Therapeutics SA

Summary 
Presently, Patrick van Berkel occupies the position of Chief Scientific Officer for ADC Therapeutics SA.

He previously held the position of VP-Antibody, Technology & Chemistry at Genmab A.

He received an undergraduate degree from Radboud University Nijmegen and a doctorate from the University of Leiden.




Current positions of Patrick van Berkel 
Holdings of Patrick van Berkel 
Patrick van Berkel : Personal Network 
Most Read News 
11/20Buffett's Berkshire boosts stakes in Japan's five biggest trading houses
RE
11/17Brazil's Buffett-backed StoneCo nearly doubles profits on more users, bigger prices
RE
11/23Berkshire Hathaway says Warren Buffett donates shares to family charities
RE
11/18Gates Foundation pledges $7 billion for Africa as Ukraine war diverts donor cash
RE
11/17After Elon Musk's ultimatum, Twitter employees start exiting
RE
11/14Buffett-backed Nubank's revenue surges on robust customer growth
RE
11/18Musk's pay trial asks if Tesla's growth justifies $56 billion compensation
RE
11/16Twitter's ex-CEO Jack Dorsey says will not retake role
RE
11/22'Boomerang CEOs' don't always work out; Disney hopes this one bucks trend
RE
11/17Zuckerberg says WhatsApp business chat will drive sales sooner than metaverse
RE
More news


© 2022 People and Ownership :   
Patrick van Berkel : Connections 


Latest news about Patrick van Berkel 
06/08Transcript : Koninklijke Vopak N.V. - Analyst/Investor Day
CI
03/25EU-U.S. data transfer deal cheers business, but worries privacy activists
RE
02/08Transcript : ADC Therapeutics SA - Special Call
CI
2021Africa needs to make own vaccines but hurdles are high, experts say
RE
2021South Africa's Biovac to start making Pfizer-BioNTech COVID-19 vaccine in early 2022 - exec
RE
2021South Africa's Biovac to start making Pfizer-BioNTech COVID-19 vaccine in early 2022 - exec
RE
More news